We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
The purpose and clinical utility of this FISH assay is to evaluate a patient tumor sample for the presence of a RET gene rearrangement. Tumors that contain a RET gene rearrangement may be responsive to treatment with tyrosine kinase inhibitor drug therapy such as vandetanib or cabozantenib. Therefore, patients that are positive for the rearrangement may benefit from this treatment. Tumor types that contain RET gene translocations that have been described include those resulting from non-small cell lung cancer as well as thyroid cancer.
Disease State: Mesothelioma vs. Adenocarcinoma
CPT Code(s): 88374 (reference only; CPTs may vary)
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
• Formalin-fixed, paraffin-embedded tissue block or cell block - OR - • Minimum of 5 unstained slide cut at 4µm for each test requested